UpDoc Debuts First FDA-Cleared Agentic Clinical AI Platform for Real-Time Patient Care
核心洞察
UpDoc (搜索) received FDA clearance for the first Software as a Medical Device (SaMD) that uses patient-facing large language models, marking a historic regulatory milestone for agentic clinical AI.
The platform enables licensed clinicians to deploy AI agents integrated with EHRs to autonomously manage chronic disease tasks such as medication titration and lab ordering between scheduled visits.
UpDoc (搜索) has secured $18 million in oversubscribed seed financing from investors including Eli Lilly, Mayo Clinic, and the American Diabetes Association.
PALO ALTO, Calif., June 25, 2026 — UpDoc (搜索), an enterprise-ready clinical AI company developing physician-grade agentic AI, announced FDA clearance for the first Software as a Medical Device (SaMD) that uses patient-facing large language models. The regulatory milestone arrives alongside $18 million in oversubscribed seed financing and initial deployments at four of the nation's leading health systems, positioning the company at the forefront of a rapidly emerging category: clinical AI that delivers care historically requiring a licensed clinician.
"We fundamentally believe that clinical AI should be held to the highest standard," said Sharif Vakili, MD, MBA, MS, CEO of UpDoc (搜索). "This FDA clearance marks a historic milestone for the field and the beginning of a new era in clinical care, where clinicians will be able to deploy clinical AI agents to help complete tasks autonomously on their behalf, much like engineers deploy coding agents today."
A Purpose-Built Clinical Operating System
Unlike consumer-facing AI assistants or generalized applications built on foundation models, UpDoc (搜索) was purpose-built as a clinical operating system embedded directly into provider workflows. At the core of the platform is UpDoc Clinical Intelligence, a proprietary orchestration and safety architecture that unifies clinical guidelines, longitudinal patient context, physician governance, and electronic health record (EHR) data to coordinate and execute real-world clinical care safely at scale.
The platform automates interventions that traditionally required a physician's direct, hands-on involvement — including adjusting medications, facilitating lab orders, and coordinating with care teams. In a representative use case, for a patient with Type 2 diabetes (搜索) whose blood glucose has been drifting out of range, UpDoc (搜索)'s platform identifies the trend, initiates a titration of the patient's insulin regimen within physician-approved parameters, triggers the appropriate follow-up test to confirm safety, and documents the entire intervention in the EHR — without the patient ever needing to schedule an appointment.
Investor Backing and Strategic Partnerships
UpDoc (搜索) has secured $18 million in oversubscribed seed financing from leading healthcare investors and strategic partners, including the American Diabetes Association, Cathay Innovation, Eli Lilly and Company, Mayo Clinic, Oxeon, Pear VC, Polaris Partners, and Section 32. This financing will accelerate UpDoc's efforts to safely and responsibly scale clinical AI across provider settings with traceable accountability.
"Where others have moved quickly to call AI a doctor, UpDoc (搜索) has invested time developing an FDA compliant system," said Andy Conrad, PhD, partner at Section 32 and former Verily CEO. "UpDoc didn't just redefine the clinical AI category. They have established what it means to do it responsibly."
Clinical Deployment and Health System Adoption
UpDoc (搜索)'s clinical AI platform follows a landmark clinical trial led by its founders at Stanford Medicine and is undergoing initial deployment at premier healthcare systems, including Cleveland Clinic, Allegheny Health Network (搜索) (AHN), and UCSF Health (搜索), with plans for broader expansion underway.
"Chronic disease management has always been constrained by the episodic nature of care delivery," said Desi Kotis, PharmD, chief pharmacy executive at UCSF Health (搜索) and vice dean of clinical affairs at UCSF School of Pharmacy. "The next frontier is making care continuous with smarter coordination between visits. Clinical AI that embeds meaningfully into how care teams work has the potential to bend the curve on some of the most persistent challenges in population health."
Amy Crawford-Faucher, MD, chair of AHN Primary Care Institute, emphasized the platform's potential to empower primary care clinicians: "The future integration of UpDoc (搜索) within our electronic health records will further strengthen care coordination, reduce administrative burden and enable our physicians to devote more of their time to high-value, clinical decision-making — ultimately driving improved long-term health outcomes for our patients and improved population health."
Redefining the Clinical AI Category
UpDoc (搜索)'s platform moves beyond traditional administrative AI use cases — such as outreach, scheduling, and billing inquiries — to help health systems scale more proactive, personalized care. Licensed clinicians can deploy FDA-cleared AI agents integrated with a provider's EHR, enabling AI agents to extend clinical reach between scheduled visits as an integral member of the care team.
The company's approach directly addresses what Vakili described as "some of the healthcare system's most pressing challenges: patient access, rising system costs and clinician burnout," with the potential to make primary care viable again. The platform enables patients to access continuous, high-touch care once reserved for concierge medicine while empowering health systems to manage patients proactively between visits, yielding unprecedented access to care, deeper population health visibility, new revenue growth, and reduced workforce strain.